The company launched a Phase 2 Long COVID study to evaluate whether immune activation with Anktiva can improve recovery by ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

UCLA researchers developed a human stem cell-derived cell therapy for an aggressive type of breast cancer. This study focused ...

Durable complete responses with CAR-NK + Rituximab in patients who failed current standards of care in Waldenstrom’s Non-Hodgkins lymphoma (NHL). Long-term evaluable patients demonstrate ongoing ...

First Phase 2 chemotherapy-free, lymphodepletion-free, off-the-shelf CAR-NK cell therapy plus ANKTIVA® and rituximab regimen to be evaluated in indolent non-Hodgkin lymphoma (iNHL), including ...

Shares of ImmunityBio (IBRX) gained more than 3% in pre-market trading on Friday, after the pharmaceutical firm announced on Friday the completion of key manufacturing engineering programs supporting ...

GC Cell announced on the 27th that it presented interim Phase 1 clinical trial results for its allogeneic umbilical cord ...

CD19 CAR-NK cell therapy with rituximab achieved durable complete responses in Waldenström Non-Hodgkin lymphoma, with up to 15 months of remission. The QUILT-106 study reported 100% disease control ...

CD19 CAR NK cell therapy, alone or with rituximab, shows promise in relapsed/refractory B-cell NHL, including Waldenström macroglobulinemia. Two heavily pretreated WM patients achieved complete ...

SENTI-202, a CAR NK cell therapy, achieved complete remission in several relapsed/refractory AML patients, showing potential as an effective treatment option. The off-the-shelf nature of SENTI-202 ...

COEPTIS, Inc. has established GEAR Therapeutics as a majority-owned subsidiary to advance its GEAR-modified natural killer (NK) cell therapy into first-in-human studies targeting various cancers and ...